Yale-New Haven Hospital physicians perform a wide array of procedures to treat structural heart disease, including surgical and transcatheter aortic valve replacement (TAVR), mitral valve repair, and patent foramen ovale (PFO) closure.
In addition to an outpatient aortic valve clinic, a multidisciplinary clinical team at YNNH has been assembled for the TAVR program that includes interventional cardiology, cardiovascular research, cardiovascular surgery, anesthesia, cardiac rehabilitation, cardiovascular imaging, intensive care, and step-down expertise.
Current structural heart disease research at Yale includes studies investigating:
Transcatheter aortic valve replacement (TAVR/TAVI)
- Medtronic CoreValve US Pivotal Trial – An evaluation of the safety and efficacy of the CoreValve System in high-risk surgical patients with severe symptomatic aortic stenosis
- CAS - Medtronic CoreValve Continued Access Study (Extreme and High Risk Patients)
- EUS - Medtronic CoreValve Expanded Use Study
- SURTAVI - Medtronic SURTAVI - Surgical Replacement and Transcatheter Aortic Valve Implantation
- NeuroTAVI - Neurological complications of contemporary unprotected TAVR (Yale NeuroTAVR)
- CHAMPION - Championing High Quality Care for the Patient with Aortic Stenosis
- PORTICO - Portico Re-Sheathable Transcatheter Aortic Valve System US IDE Trial
- EVOLUT R - The Medtronic CoreValve "Evolut" R US Clinical Study
- SALUS - TranScatheter Aortic Valve RepLacement System a US Pivotal Trial
Mitral valve therapy
- Surgical Interventions for Moderate Ischemic Mitral Regurgitation – An NHLBI/ Cardiothoracic Surgery Clinical Trials Network examination of valve repair versus replacement in patients with severe mitral regurgitation caused by coronary artery disease
- COAPT - Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation
- This non-randomized, prospective, interventional observational multi-center study is designed to assess the long-term clinical performance of the Medtronic Melody™ Transcatheter Pulmonary Valve (TPV) in the post market environment over a period of five years after transcatheter implantation in patients with dysfunctional RVOT conduits.
Percutaneous patent foramen ovale (PFO) closure
Associate Professor of Medicine (Cardiology)
Director, Cardiac Catheterization Laboratory, VA Connecticut